Short CommunicationNuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin
Section snippets
Introduction, M&M, Results and Discussion
Dengue virus (DENV), a mosquito-borne human pathogen encompassing 4 distinct but closely related serotypes, is a threat to >40% of the world’s population. It contains a positive-sense, single-stranded RNA genome that is translated and replicated in the host cell cytoplasm, encoding three structural (capsid, pre-membrane/membrane, and envelope) and seven nonstructural (NS) proteins (Lindenbach et al., 2007). The multifunctional NS5 is the most conserved amongst DENV1–4, comprising an N-terminal
Acknowledgements
We thank Lee Chin Chin, Sabrina Koh and Elfin Lim for assistance with phage display and preparation of NS5 antibodies, Zhao Yong Qian and Brendon Hansen for NS5 and IgG expression plasmids, respectively, and Amy Rogers and Cassandra David for technical assistance. This work was supported by the National Health and Medical Research Council Australia (Project Grant ID#606409 and Senior Principal Research Fellowship APP1002486), DUKE-NUS Signature Research Program (funded by the Ministry of
References (35)
- et al.
De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase
J. Biol. Chem.
(2001) - et al.
The interdomain region of dengue NS5 protein that binds to the viral helicase NS3 contains independently functional importin beta 1 and importin alpha/beta-recognized nuclear localization signals
J. Biol. Chem.
(2002) - et al.
Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?
Antiviral Res.
(2012) - et al.
Structural basis for the specificity of bipartite nuclear localization sequence binding by importin-alpha
J. Biol. Chem.
(2003) - et al.
CRM1 is an export receptor for leucine-rich nuclear export signals
Cell
(1997) - et al.
The 37-amino-acid interdomain of dengue virus NS5 protein contains a functional NLS and inhibitory CK2 site
Biochem. Biophys. Res. Commun.
(1999) - et al.
Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5
J. Biol. Chem.
(1995) - et al.
Monoclonal antibodies against dengue NS2B and NS3 proteins for the study of protein interactions in the flaviviral replication complex
J. Virol. Methods
(2012) Ivermectin: 25 years and still going strong
Int. J. Antimicrob Agents
(2008)- et al.
Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model
Antiviral Res.
(2011)
CRM1-mediated nuclear export of dengue virus RNA polymerase NS5 modulates interleukin-8 induction and virus production
J. Biol. Chem.
Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence
Cell
Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors
Antiviral Res.
Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity
Virology
Intramolecular masking of nuclear localization signals: analysis of importin binding using a novel AlphaScreen-based method
Anal. Biochem.
An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import
J. Biomol. Screen.
Nuclear import of HSV-1 DNA polymerase processivity factor UL42 is mediated by a C-terminally located bipartite nuclear localization signal
Biochemistry
Cited by (229)
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
2023, Journal of Pharmacological SciencesRecent advances in the development of methyltransferase (MTase) inhibitors against (re)emerging arboviruses diseases dengue and Zika
2023, European Journal of Medicinal ChemistryIvermectin systemic availability in adult volunteers treated with different oral pharmaceutical formulations
2023, Biomedicine and Pharmacotherapy
- 1
These authors contributed equally as first authors to this work.
- 2
These authors contributed equally as senior authors to this work.